The global anatomic pathology market size was valued at USD 16.06 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 10.08% from 2021 to 2028. An increase in the clinical use ofbiomarkersenables the pathologists to determine disease pathogenesis at the molecular level and further guides the clinical decision-making, thereby improving patient outcomes. The growing reliance on biomarkers-based pathology tests and procedures to explore common malignancy and tumorigenesis is driving the market. The COVID-19 pandemic is serving as a driver for the adoption of whole slide imaging,digital pathology, telepathology。数字病理帮助pathologists work remotely, enhancing their overall productivity and helping them address the backlog of cases. The usage rate of these technologies has been gaining momentum over the past few years. The COVID-19 pandemic has further boosted this adoption, in turn, having a positive impact on the market growth.
高使用先进的病理设备往下h as staining systems, gross imaging, and digital microscopes is poised to improve anatomic pathological practices to a major extent. The digital imaging solutions offer specificity and accuracy-related benefits over the conventional techniques, which in turn, boosts the service uptake rate in the market for anatomic pathology.
Companies are undertaking continuous efforts for the development of advanced and upgraded pathology equipment with respect to their design and ease of use. For instance, in May 2021, a digital pathology solutions provider-OptraSCAN introduced CytoSiA-an intelligent solution for affordable and rapid scanning and analysis of pap smears and liquid-based cytology slides. This instrument allows whole slide cytology imaging with advanced image analysis.
Moreover, several partnership and agreement ventures among key companies for the introduction of an effective portfolio are driving the market. For instance, in April 2021, Royal Philips collaborated with Ibex Medical Analytics, a company involved in AI-based cancer diagnostics, to boost the adoption of AI-based digital pathology. Both the companies combined their expertise to offer advanced solutions to empower pathologists.
The growing focus on personalized medicine and the increasing incidence rate of cancer and other chronic disorders are some of the factors driving the market growth. Moreover, increasing reliance on biomarkers-based pathology procedures and tests to explore tumorigenesis and common malignancy is also driving the market. Clinically useful biomarkers are used for the development of diagnostic tests and therapeutic drugs. Pathological laboratories can rely on these biomarkers to detect & track infections and disease progression during diagnostic procedures. Hence, biomarkers are gaining ground as diagnostic and prognostic markers.
The high usage of advanced pathology systems such as digital microscopes, gross imaging, and staining systems is poised to enhance anatomic pathological practices to a major extent. The digital imaging solutions provide accuracy and specificity related benefits over the conventional techniques, thereby propelling the service uptake rate in the anatomic pathology market.
Furthermore, key entities are undertaking several strategic initiatives to develop upgraded and advanced pathology devices with respect to their design and ease of use. For instance, in April 2021, Leica Biosystems signed a strategic collaboration with Paige, an AI-based company with an aim to develop computational pathology systems. The company undertook this strategic step to an expansion of its digital pathology product portfolio. Similarly, in May 2021, Quest Diagnostics announced its partnership with Paige to develop AI-based cancer pathology products.
A major restrain affecting market growth is higher rate of errors, which widely varies across institutions and as per test type. In a laboratory medicine workflow, error rates can vary from 32% to 75% in the pre-analytic phase, 13% to 32% in analytic phase, and 9% to 31% in post analytic phase. Common errors may arise due to patient or specimen misidentification, specimen contamination, and specimen collection errors. Larger laboratories accessioning 20,000 or more specimens per year face high rate of discrepancies as compared to those receiving less than 20,000 samples.
Moreover, the availability of refurbished anatomic pathology systems has impeded the growth of this space. International Equipment Trading Ltd., LabX, ReScience, and AL-TAR are some of the entities offering refurbished anatomic pathology systems such as microtomes, ICH& ISH, and staining systems. Mainly medium and small-sized laboratories in developing countries opt for refurbished systems due to the high prices of instruments. This factor is anticipated to increase the demand for refurbished instruments, thereby restraining the market growth.
The consumables segment dominated the market in 2020 with a share of over 65.0%. The availability of a wide range of products, coupled with a high usage rate of consumables in research findings, is fueling the segment growth. The low cost and the easy availability of pathology consumables further contributed to the segment growth.
A substantial number of reagents and kits, antibodies, and probes are being marketed for anatomic pathology protocols. Some key reagents and kits include Tamping Tools Kits, CISH Centromere Detection Kits by Thermo Fisher; ultra view SISH DNP Detection Kit, ISH iVIEW Blue Plus Detection Kit by Roche, and Instrument Cleaning Kit by Agilent.
The ongoing technological advancements and focused efforts by the market participants to offer anatomic pathological instruments with an improved design are anticipated to bolster the growth of the instruments segment. For instance, in April 2020, Precisionary Instruments launched a CF-6100 cryostat. This cryostat promotes and supports tissue sectioning in dermatology, histology, and pathology.
The disease diagnosis segment accounted for the largest share of over 55.0% in 2020. Pathology protocols provide an opportunity for researchers to explore disease etiology and associated outcomes. Thus, the market is witnessing the wide application of anatomic pathology in disease diagnosis. The rising prevalence of chronic conditions, such as cancer, along with the surging geriatric population, is the major factor driving the disease diagnosis segment.
The anatomic pathology workflow aids the detection of a tumor at the inflammatory and proliferating stromal cells stage, thus minimizing costs associated with tumor eradication. In addition, the increasing focus of the manufacturers on the introduction of innovative and novel diagnostics techniques accelerates the segment growth.
The drug discovery and development segment is anticipated to grow at a lucrative pace over the forecast period. Tissue analysis carried out by the pathologists generates a wealth of information for pharmaceutical manufacturers during preclinical trials. Anatomic pathology plays a vital role in toxicology assessment for the evaluation of the adverse effects of candidate drugs.
The hospitals segment dominated the market with a revenue share of over 45.0% in 2020 owing to the high hospitalization rate of cancer patients, coupled with a substantial number of frequent readmissions in hospitals. Moreover, the presence of well-developed infrastructure, coupled with a well-trained staff in hospital-based pathological laboratories, stimulates the growth of the hospital segment.
The hospital segment is also expected to be befitted by an increasing number of initiatives undertaken by the public and private agencies to promote advanced healthcare systems. The emergence of advanced testing techniques and equipment has led to a lucrative growth of the diagnostic laboratories segment.
通过各种大量的临床试验ongoing projects spurs the growth of the research laboratories segment. Research laboratories are engaged in offering rapid and comprehensive information about the functioning of diseased tissues, with the overall objective of achieving a high degree of patient satisfaction.
North America dominated the anatomic pathology market and accounted for the largest revenue share of 46.5% in 2021. The region is anticipated to continue its dominance over the forecast period. This growth can be attributed to a presence of well-established players, growing implementation of digital pathology services with advanced imaging tools, rising awareness about regular health screening, and favorable government reimbursement policies.
Efforts by key players for maintaining their share drive the U.S. market to a dominant position. For instance, In September 2021, Agilent Technologies announced strategic collaboration with Visiopharm to expand its (AI)-driven precision pathology software globally. Such partnerships are anticipated to supplement market growth.
China anatomic pathology market is booming due to several Chinese pathology congresses conducted in the country in the past few years. For instance, the 2nd Digital Pathology & AI Congress: China is expected to be held in September 2022 in China. This meeting is aimed at increasing the implementation of digital pathology to enhance workflow efficiency and standardization of image analysis.
Anatomic pathology is a mature industry with a large number of key players in it. The advent of new strategic plans to maintain competitiveness stimulates market growth. The market is well equipped with upcoming and innovative instruments and consumables to address the challenges in transforming pathology trends.
例如,2021年9月,罗氏宣布the launch of digital pathology open environment. The new workflow allows researchers and physicians to share images for better analysis. Further, the platform is compatible with whole slide imaging technology. Hence, the ongoing strategies adopted by key players boost the market growth as it helps retain their leadership in the market. Some prominent players in the global anatomic pathology market include:
Danaher Corporation
PHC Holdings Corporation
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
F. Hoffmann-La Roche AG
Agilent Technologies, Inc.
Cardinal Health
Sakura Finetek USA, Inc.
NeoGenomics Laboratories, Inc.
BioGenex
Bio SB
Report Attribute |
Details |
Market size value in 2021 |
USD 17.70 billion |
Revenue forecast in 2028 |
USD 34.66 billion |
Growth rate |
CAGR of 10.08% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2017 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product & services, application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; U.K., China; India; Brazil; Mexico, South Africa |
Key companies profiled |
Danaher Corporation; PHC Holdings Corporation; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche AG; Agilent Technologies, Inc.; Cardinal Health; Sakura Finetek USA, Inc.; NeoGenomics Laboratories, Inc.; BioGenex; Bio SB |
Customization scope |
Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs.Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global anatomic pathology market report on the basis of product and services, application, end-use, and region:
Product & Services Outlook (Revenue, USD Million, 2017 - 2028)
Instruments
Microtomes & Cryostat
Tissue Processors
Automatic Stainers
Whole Slide Imaging (WSI) Scanners
Other Products
Consumables
Reagents & Antibodies
Probes & Kits
Others
Services
Application Outlook (Revenue, USD Million, 2017 - 2028)
Disease Diagnosis
Drug Discovery and Development
Others
End-use Outlook (Revenue, USD Million, 2017 - 2028)
Hospitals
Research Laboratories
Diagnostic Laboratories
Others
Regional Outlook (Revenue, USD Million, 2017 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
China
India
Latin America
Brazil
Mexico
Middle East and Africa (MEA)
South Africa
b.The global anatomic pathology market size was estimated at USD 16.06 billion in 2020 and is expected to reach USD 17.70 billion in 2021.
b.The global anatomic pathology market is expected to grow at a compound annual growth rate of 10.08% from 2021 to 2028 to reach USD 34.66 billion by 2028.
b.Some key players operating in the anatomic pathology market include Cardinal Health, Inc.; F. Hoffmann-La Roche AG; Agilent Technologies, Inc.; Sakura Finetek USA, Inc.; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; NeoGenomics Laboratories, Inc.; BioGenex; PHC Holdings Corporation and Bio SB.
b.Key factors that are driving the anatomic pathology market growth include implementation of biomarker-based disease assessments, rising competitiveness among the market vendors, a substantial number of supporting programs and training modules by the government, and increasing incidence of chronic disorders.
b.Key anatomic pathology market opportunities include a growing focus on tissue base diagnostic procedures and the emergence of automated systems in the market space.
"The quality of research they have done for us has been excellent."